SNDX - Syndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84 revenue of $126.6M beats by $67.92M March, 01 2022 04:21 PM Syndax Pharmaceuticals Inc. Syndax Pharmaceuticals press release (NASDAQ:SNDX): Q4 GAAP EPS of $1.81 beats by $1.84. Revenue of $126.6M (+63200.0% Y/Y) beats by $67.92M. For further details see: Syndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92M